A Randomized, Multicenter, Double-Blind, 6 Week Study to Evaluate the Dose Response of Valsartan on Blood Pressure Reduction in Children 6 Months - 5 Years Old With Hypertension, Followed by a 2 Week Placebo Withdrawal Period.
Phase of Trial: Phase III
Latest Information Update: 30 Sep 2017
At a glance
- Drugs Valsartan (Primary)
- Indications Hypertension
- Focus Therapeutic Use
- Sponsors Novartis Pharmaceuticals Corporation
- 14 May 2012 Actual patient number for the extension trial (NCT00457626) is now 66.
- 14 May 2012 Actual end date for the extension trial (NCT00457626) is now May 2009
- 14 May 2012 Actual initiation date for the extension trial (NCT00457626) is now Apr 2007.
Most Recent Events
Table of Contents
- At a glance
- Trial Overview
- Trial Details
- Trial Centres
- Trial History